Tevogen Bio's Long COVID Therapy Shows 100% Efficacy in PoC Data, Expands Patient Eligibility to 65% US Population
TVGN sits 17% above its 52-week low of $6.218.
Summary
Tevogen Bio Holdings Inc. provided a significant update on its TVGN 489 program for Long COVID, reporting positive proof-of-concept data where 100% of treated high-risk patients did not develop the condition. The company also announced the identification of five additional HLA targets, expanding TVGN 489's potential eligibility to approximately 65% of the U.S. population, which is a material increase in market opportunity. Following the recent appointment of a new leadership team, Tevogen is accelerating its clinical development for TVGN 489 and is evaluating the acquisition of Sciometrix and its Clinicus platform to integrate digital health monitoring. This strategic focus on clinical advancement and digital integration, alongside recent capital structure adjustments and other acquisition evaluations, indicates a concerted effort to progress its core therapeutic pipeline.
At the time of this announcement, TVGN was trading at $7.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.6M. The 52-week trading range was $6.22 to $75.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.